1. Introduction
===============

Pancreatic surgery is a complex procedure that requires a high level of expertise.^\[[@R1]\]^ Improvements in perioperative management have successfully reduced the mortality rates associated with pancreatic surgery, but morbidity remains high.^\[[@R2]\]^ Up to 40% of patients develop complications following pancreatic resection. Postoperative complications not only impact the patient\'s quality of life, but can also delay adjuvant therapy and adversely impact survival. It is therefore crucial to identify high-risk patients who are likely to develop postoperative complications.

Pancreatic pathologies are often characterized by a marked nutritional imbalance, ranging from undernutrition to cachexia.^\[[@R3]\]^ This imbalance results from a combination of decreased caloric intake and increased catabolism caused by pancreatic diseases. Undernutrition has recently been proposed as a robust predictor of postoperative complications and poor prognosis after pancreatic resection.^\[[@R4],[@R5]\]^ Undernutrition implies a loss of fat mass that is frequently associated with muscle decline or sarcopenia. Sarcopenia was described in 1989 by Rosenberg as a decrease in skeletal muscle mass occurring with aging^\[[@R6]\]^ and was described as a qualitative alteration in muscle function.^\[[@R7]\]^

Sarcopenia appears to have a negative impact on surgical outcomes after hepatectomy,^\[[@R8],[@R9]\]^ colorectal resection,^\[[@R10]--[@R12]\]^ gynaecological surgery,^\[[@R13]\]^ and cardiac surgery.^\[[@R14]\]^ It was also reported as a predictor of poor prognosis in colorectal cancer,^\[[@R11],[@R15]\]^ oesophago-gastric cancer,^\[[@R16],[@R17]\]^ hepatocellular carcinoma,^\[[@R18],[@R19]\]^ and pancreatic adenocarcinoma (PDAC).^\[[@R20]--[@R23]\]^

Nevertheless, data regarding the impact of sarcopenia on outcomes following pancreatic surgery are scarce, with only a few studies focusing on patients with PDAC. Therefore, the purpose of this study was to evaluate the prevalence of sarcopenia in patients undergoing pancreatic surgery for benign or malignant diseases and to examine its impact on the postoperative course and patient survival.

2. Materials and methods
========================

2.1. Patients
-------------

We retrospectively reviewed all consecutive patients who underwent pancreatic resection (including pancreaticoduodenectomy \[PD\], distal pancreatectomy \[DP\], and total pancreatectomy \[TP\]) for a benign or malignant disease in our department between May 2011 and July 2015. In order to determine the impact of sarcopenia on postoperative outcome and survival, we excluded patients who had: undergone preoperative abdominal computed tomography (CT) (within 6 weeks prior to surgery) at outside institutions; undergone another surgical procedure (such as enucleation, central pancreatectomy, or Wirsung derivation); no dosing of drain amylase or hyperamylasaemia on postoperative day (POD) 3 for the diagnosis of postoperative pancreatic fistula (POPF); and (iv) a surgical emergency. This study was approved by our institution\'s ethics committee.

2.2. Data collection
--------------------

For each patient, the following data were collected from a computerized database: age, sex, date of birth, medical and surgical history, American Society of Anesthesiologists (ASA) score, weight, height body mass index (BMI), percentage of body weight loss, and preoperative biological tests (including aspartate aminotransferase, AST; alanine aminotransferase, ALT; total and combined bilirubin; and creatinine and albumin levels).

A patient was considered as undernourished if one of the following criteria was present: estimated weight loss was ≥5%, BMI was \<21 kg/m^2^, and albumin level was \<35 mg/L. Preoperative nutrition support was performed for patients who met the undernutrition criteria.

Intraoperative data, including operative time, estimated blood loss (EBL), intraoperative blood transfusion, pancreatic texture, surgical approach, vascular resection, drainage, and main pancreatic duct diameter were extracted from the pancreas database.

Complications at 3 months postoperatively were rated according to the Clavien--Dindo classification,^\[[@R24]\]^ where severe complications were defined by a grade ≥3. POPF was defined according to the International Study Group of Pancreatic Fistula (ISGPF) and classified into grades A, B, or C.^\[[@R25]\]^

Bleeding and postoperative gastroparesis were graded according to the international consensus.^\[[@R26],[@R27]\]^ Length of stay (LOS) was also assessed. Operative mortality was defined as death within 90 days after surgery or before discharge from the hospital. For the purposes of survival analysis, only patients with cancer diseases were analysed.

2.3. Sarcopenia measurement
---------------------------

Sarcopenia was assessed by measuring the total cross-sectional muscle area (including of the psoas muscles; paraspinal, external, and internal oblique muscles; and the transverse and rectus abdominal muscles). The total muscle area was measured semiautomatically by manually outlining them on preoperative plain CT at the third lumbar vertebra (L3) and setting the density at a threshold of −29 to +150 (Fig. [1](#F1){ref-type="fig"}). All of the measurements and calculations described above were performed by the same examiner (MV), who was blinded to the surgical outcome at the time of quantification. We used the sarcopenia definition proposed by Prado et al.^\[[@R28]\]^ According to this definition, sarcopenia was defined using the following criteria: skeletal muscle index (SMI) \<38.5 cm^2^/m^2^ for women or \<52.4 cm^2^/m^2^ for men (SMI \[cm^2^/m^2^\] = \[total muscle area at L3\]/\[height\]^2^).

![Skeletal muscle index was measured at the level of L3 by measuring a total muscle area. Measurements were performed semi-automatically with manual outlining of abdominal muscles.](medi-97-e12076-g001){#F1}

2.4. Statistical analysis
-------------------------

Statistical analyses were implemented with SPSS software, version 21.0 (SPSS, Chicago, IL). Continuous variables, expressed as means ± standard deviations, were compared using the Mann--Whitney U test. Binary and categorical variables were compared with either the chi-squared test or Fisher\'s exact test. Cumulative overall survival (OS) and disease-free survival rates were calculated using the Kaplan--Meier method, and the differences between the curves were evaluated using a log-rank test. Comparisons were performed between sarcopenic and nonsarcopenic patients. Nonsarcopenic patients were stratified by BMI with the aim of considering the impact of being overweight on outcomes following pancreatic surgery.

To assess the independent contribution of each variable, a Cox proportional hazards regression model was utilized. Significance was set at *P \< *.05.

3. Results
==========

3.1. Demographic characteristics
--------------------------------

The clinical and pathological characteristics of the 107 patients included in the study are outlined in Table [1](#T1){ref-type="table"}. The mean age of the study sample overall was 61 ± 12 years. There were 51 (48%) men and 56 (52%) women. Pancreatic surgery was performed for malignant disease in 77 cases (72%), of which PDAC was the predominant aetiology (53%). Of the 107 patients, 82 (77%) underwent PD and 65 (60%) met the criteria of undernutrition. The prevalence of sarcopenia was 47% in our cohort. There was a similar rate of sarcopenia in patients with malignant or benign disease (44% vs 53%, respectively). Compared to the nonsarcopenic patients, the sarcopenic group was characterized by a higher proportion of men (Table [2](#T2){ref-type="table"}, Fig. [2](#F2){ref-type="fig"}) and a lower BMI. Groups were comparable regarding other pre- and intraoperative parameters (Table [2](#T2){ref-type="table"}).

###### 

Characteristics of the population study (n = 107).
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###### 

Clinical characteristics of sarcopenic and nonsarcopenic patients.
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![Distribution of skeletal muscle index according to age (A) and gender (B).](medi-97-e12076-g004){#F2}

3.2. Impact of sarcopenia on 3-month mortality and the postoperative course
---------------------------------------------------------------------------

The 3-month mortality was comparable between groups. Severe complications were reported in 6 (12%) sarcopenic and 13 (22%) nonsarcopenic patients. Unexpectedly, POPF occurred more frequently in the nonsarcopenic group (70% vs 36% in sarcopenic patients), although the rates of severe POPF (i.e., grades B and C) were comparable between groups. Regarding other complications, the rates of gastroparesis, infectious complications, and reoperation were similar between groups. LOS was also similar between sarcopenic and nonsarcopenic patients.

To identify potential confounding factors for postoperative morbidity and mortality, we further stratified the patients according to their BMI (\<25 kg/m^2^ or ≥25 kg/m^2^). Overall, major complications primarily occurred among sarcopenic (12%) or overweight nonsarcopenic patients (30%) rather than among nonoverweight, nonsarcopenic patients (6%, *P = *.03). Similarly, POPF grades B or C and death occurred exclusively among sarcopenic or overweight nonsarcopenic patients. In addition, the LOS was significantly longer among sarcopenic patients (21.9 days) and overweight nonsarcopenic patients (22.2 days), compared to 14.5 days for the nonoverweight, nonsarcopenic patients (*P = *.003) (Table [3](#T3){ref-type="table"}).

###### 

Hospital stay and mobimortality of sarcopenic and overweight no sarcopenic patients.

![](medi-97-e12076-g005)

3.3. Impact of sarcopenia on survival
-------------------------------------

PDAC was the most frequent indication for pancreatic surgery in our study. Among cancer patients (n = 77) treated with pancreatectomy, 31 (40%) experienced disease recurrence, and 23 (30%) died after 15 ± 13.5 months. The median disease-free survival was 11.1 ± 2.6 months in the sarcopenic group compared to 22.5 ± 15 months in the nonsarcopenic group (*P = *.04). OS was also lower in the sarcopenic group (16 ± 3.6 months in the sarcopenic group vs not achieved in the nonsarcopenic group, *P = *.02) (Fig. [3](#F3){ref-type="fig"}). We also analysed the 1- and 2-year OS rates between sarcopenic and nonsarcopenic patients. Survival within 1 to 3 years postoperatively were higher among the nonsarcopenic than among the sarcopenic patients (66% vs 45%, *P = *.02, and 58% vs 38%, *P = *.02, respectively).

![Overall and disease free survival according to sarcopenic status in patients with malignant diseases.](medi-97-e12076-g006){#F3}

We also examined the impact of being overweight on OS and disease-free survival (Fig. [4](#F4){ref-type="fig"}). Interestingly, overweight patients (BMI \> 25 kg/m^2^) had poorer long-term prognoses, as shown by the overall disease-free survival curves in Figure [4](#F4){ref-type="fig"}.

![Overall and disease free survival of sarcopenic and nonsarcopenic patients stratified by BMI.](medi-97-e12076-g007){#F4}

The multivariate analysis showed that sarcopenia tended to increase the risk of death (hazard ratio, 2.04; 95% confidence interval, 0.93--4.49; *P = *.07; Table [4](#T4){ref-type="table"}).

###### 

Univariable and multivariable cox proportional hazards regression analysis of overall survival.
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4. Discussion
=============

Pancreatic surgery is a complex procedure with a high rate of morbidity. It is challenging to identify preoperatively the patients at risk of experiencing complications in order to improve their postoperative outcomes. Preoperative evaluation of nutritional status can predict these complications, as it is a significant factor that affects postoperative outcomes.^\[[@R29]\]^ However, nutritional assessment requires clinical and biological data whose relevance and reproducibility remain insufficient. Sarcopenia, on the other hand, is an assessment of muscle reserve that reflects the nutritional status. Here, we analysed the impact of sarcopenia on postoperative outcomes and survival in a series of 107 patients. Even though there was no significant difference between the 2 groups with respect to overall morbidity and death rates, POPF grades B or C and deaths occurred exclusively in the sarcopenic patients or overweight nonsarcopenic patients, who had significantly longer LOSs. These results are consistent with data reported in literature. Joglekar et al,^\[[@R30]\]^ showed in 118 patients that sarcopenia was an independent predictor of major grade III complications; LOS; intensive care unit admission; delayed gastric emptying; and infectious, gastrointestinal, pulmonary, and cardiac complications. Similarly, Amini et al^\[[@R23]\]^ reported a correlation between sarcopenia and postoperative morbidity in a series of 763 patients. A few studies have attempted to examine the impact of sarcopenia on the POPF rate and its severity. Joglekar et al^\[[@R30]\]^ reported no correlation between sarcopenia and pancreatic fistula, but they did not analyse grades of severity. However, Nishida et al^\[[@R31]\]^ highlighted that preoperative sarcopenia was a strong and independent risk factor for clinically relevant POPF formation after PD. Despite the large numbers of patients included in these studies, their definition of sarcopenia remains unclear. In these studies, sarcopenia was not defined according to the international consensus, which was used in the present study. This limitation should be considered when interpreting the data.

Being overweight is a determinant of postoperative complications following gastrointestinal surgery.^\[[@R32]\]^ We observed that overweight patients had an equivalent behaviour to sarcopenic patients. We showed a similar rate of grades B and C POPF in sarcopenic and overweight nonsarcopenic patients. These patients also had significantly more postoperative complications and significantly longer LOSs. We could not analyse the impact of sarcopenia for overweight patients due to an insufficient number of patients. Recent data suggest, however, that this combination could influence postoperative outcomes and prognosis.^\[[@R33],[@R34]\]^

In our series, sarcopenia was a major prognostic factor among patients who underwent surgery for malignant diseases. The overall and disease-free survivals were significantly shorter in sarcopenic patients. The association between sarcopenia and survival rates has been previously studied in pancreatic disease. Peng et al reported an increased risk of death after 3 years in a large series of 557 patients undergoing pancreatectomy for PDAC.^\[[@R20],[@R22]\]^

The oncological impact of sarcopenia is multifactorial. The skeletal muscles play a fundamental role in protein synthesis, and sarcopenia might interfere with immune defence.^\[[@R35]\]^ A large number of postoperative complications in sarcopenic patients is likely to delay the time to administration of adjuvant therapy and its subsequent impact on prognosis. Moreover, the hypertoxicity of drugs in sarcopenic patients has been studied. Prado et al^\[[@R36]\]^ investigated 62 patients treated surgically for colorectal cancer and reported their tolerance towards 5-FU adjuvant chemotherapy.

Sarcopenia can also affect patients with benign disease. Sixteen patients who underwent pancreatic surgery for benign diseases were sarcopenic, and the rate of sarcopenia was comparable to that of patients treated surgically for malignant diseases. Chronic pancreatitis was the most common aetiology for pancreatectomy in our study. This entity is commonly associated with undernutrition and cachexia. To our knowledge, there are no studies on the impact of sarcopenia in patients with chronic pancreatitis. Thus, studies are needed to show whether there is sarcopenia affects these patients.

Some measures that have been proposed to treat sarcopenia have not been supported by evidence. Optimization of the patient\'s nutritional status should be achieved by adopting a program with nutritional objectives. However, no study has shown an increase in lean mass following the usual nutritional treatments. It has been suggested that physical activity may have a beneficial effect on the surgical outcomes of patients undergoing surgery for malignant disease; an American study of 252,925 patients showed that postoperative mortality was lower as the patient\'s normal physical activity levels increased.^\[[@R37]\]^ Physical activity may also improve the quality of life or even the prognosis of patients treated surgically for malignancies.^\[[@R38]\]^ A few encouraging results in the elderly show that physical activity might improve lean mass and strength.^\[[@R39]\]^

Our study has some limitations. First, our definition of sarcopenia is very restrictive. Measurement of muscle strength and grip is possible in current practice, but it requires a prospective assessment. Second, our definition of sarcopenia according to Prado\'s cut-off is based on a Canadian cohort of obese sarcopenic patients with respiratory or gastrointestinal tumours.^\[[@R28]\]^ However, this definition was the most commonly used in the literature. Moreover, Mourtzakis et al demonstrated the validity of Prado\'s cut-off in cancer patients with a strong correlation to appendicular skeletal muscle mass obtained with dual energy x-ray absorptiometry (which is the gold-standard method). Finally, our study contains some potential bias because of its retrospective design. However, only patients who had CT performed in our institution were included, allowing a homogeneous assessment of sarcopenia. Despite the study limitations, our data clearly show the clinical impact of sarcopenia in pancreatic surgery.

5. Conclusion
=============

Sarcopenia negatively impacts short- and long-term outcome in patients undergoing pancreatectomy. The measurement of skeletal muscle mass with a CT is simple and enables the selection of patients for pancreatectomy. The identification of sarcopenic patients before pancreatectomy allows the implementation of early strategies to improve muscle mass in order to improve prognosis and patient selection.
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